137 related articles for article (PubMed ID: 37203844)
21. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
22. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
[TBL] [Abstract][Full Text] [Related]
23. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
[TBL] [Abstract][Full Text] [Related]
24. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
25. MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
Fischbach F; Hass P; Schindele D; Genseke P; Geisendorf L; Stehning C; Schostak M; Brunner T; Pech M; Fischbach K
Eur Radiol; 2020 Apr; 30(4):2072-2081. PubMed ID: 31828412
[TBL] [Abstract][Full Text] [Related]
26. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
[TBL] [Abstract][Full Text] [Related]
28. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
29. [Salvage 125I brachytherapy of locally recurrent prostate cancer].
Gesztesi L; Ágoston P; Major T; Gődény M; Andi J; Lengyel Z; Polgár C
Magy Onkol; 2014 Sep; 58(3):219-24. PubMed ID: 25260087
[TBL] [Abstract][Full Text] [Related]
30. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
31. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.
Singh AK; Guion P; Susil RC; Citrin DE; Ning H; Miller RW; Ullman K; Smith S; Crouse NS; Godette DJ; Stall BR; Coleman CN; Camphausen K; Ménard C
Radiat Oncol; 2006 Aug; 1():28. PubMed ID: 16914054
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
[TBL] [Abstract][Full Text] [Related]
33. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
34. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience.
Prada PJ; González H; Fernández J; Jiménez I; Iglesias A; Romo I
BJU Int; 2012 Jun; 109(12):1787-93. PubMed ID: 21981583
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859
[TBL] [Abstract][Full Text] [Related]
36. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
Mendez LC; Ravi A; Chung H; Tseng CL; Wronski M; Paudel M; McGuffin M; Cheung P; Loblaw A; Morton G
Brachytherapy; 2018; 17(2):291-297. PubMed ID: 29137956
[TBL] [Abstract][Full Text] [Related]
37. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen-Positron Emission Tomography and Computed Tomography Imaging.
Raman S; Keyes M; Oh J; Rousseau E; Krauze A; Wilson D; Bénard F
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1126-1134. PubMed ID: 34986383
[TBL] [Abstract][Full Text] [Related]
39. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
40. 3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results.
Martin T; Hey-Koch S; Strassmann G; Kolotas C; Baltas D; Rogge B; Röddiger S; Vogt HG; Heyd R; Dannenberg T; Kurek R; Tunn U; Zamboglou N
Strahlenther Onkol; 2000 Aug; 176(8):361-7. PubMed ID: 10987019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]